Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Health Agency (DHA), on behalf of the Department of War (DoW), has issued a Solicitation for pharmaceutical agents to be considered for placement on the DoW Uniform Formulary (UF). This initiative aims to establish an effective and efficient pharmacy benefits program for the Military Health System (MHS) by awarding Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program Agreements (UF ADP). Manufacturers are invited to submit quotes for various drug classes. Quotes and responses to clinical questions are due March 26, 2026.
Opportunity Details
The DoW is legally mandated to maintain an integrated pharmacy benefits program. This solicitation seeks to obtain competitive quotes for pharmaceutical agents within specific drug classes that will be reviewed by the DoW Pharmacy and Therapeutics (P&T) Committee. The process involves evaluating clinical and cost-effectiveness to select agents for the UF and classify them for cost-sharing purposes.
Scope of Pharmaceutical Agents
The P&T Committee will review the following drug classes/subclasses in May 2026:
- Cardamyst - Calcium Channel Blocking Agents
- Myqorzo - Cardiovascular Agents Miscellaneous
- Ontralfy - Skeletal Muscle Relaxants and Combinations
- Pivya - Antibiotics - Beta-lactams
- Sdamlo - Calcium Channel Blocking Agents
- Vybrique - Phosphodiesterase-5 Inhibitors - Erectile Dysfunction
- Zycubo - Electrolyte-Mineral-Trace Element Replacement
Key Requirements for Bidders
Manufacturers must submit:
- UF BPA Quotes: For prices applicable to Military Treatment Facilities (MTF) and TRICARE Mail Order Pharmacy (TMOP).
- UF ADP Quotes: For refunds applicable to pharmaceutical agents dispensed in the TRICARE retail network.
- NDC Price List: With prices per unit of measure and per NDC-11 package.
- Clinical and Cost Effectiveness Data: Including drug properties, advantages, place in therapy, Minimum Clinically Important Difference (MCID), and patient-reported outcomes.
- An existing FSS contract / Interim Agreement is required.
- Bidders must complete applicable pages and appendices from the RFQ and Price Appendix FAQ, submitting a Quote Submission Checklist and executed signature pages.
Contract & Evaluation
- Contract Type: Blanket Purchase Agreements (BPAs) and Additional Discount Programs (ADPs).
- Period of Performance: Agreements are effective upon signature and continue until the drug class is reevaluated or terminated. Prices are valid for 180 days.
- Set-Aside: None specified.
- Evaluation Criteria: The P&T Committee will assess relative clinical effectiveness, cost effectiveness, UF BPA price quotes, and UF ADP refund quotes.
- Place of Performance: San Antonio, TX.
Important Dates & Contacts
- Published Date: February 26, 2026
- Pre-Quotation Teleconference: March 11, 2026 (details in RFQ Part 2.4)
- Quotes Due: March 26, 2026
- Responses to Clinical Questions Due: March 26, 2026
- P&T Committee Meeting: May 6-7, 2026
- Primary Contact: Julianne Canaley (julianne.m.canaley.ctr@health.mil)
- Secondary Contact: Tracy Banks (tracy.e.banks2.civ@health.mil)